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Abstract
Recent studies have shown that zinc ion (Zn) can behave as an intracellular signaling molecule. We previously demonstrated
that mast cells stimulated through the high-affinity IgE receptor (FceRI) rapidly release intracellular Zn from the endoplasmic
reticulum (ER), and we named this phenomenon the ‘‘Zn wave’’. However, the molecules responsible for releasing Zn and
the roles of the Zn wave were elusive. Here we identified the pore-forming a1 subunit of the Cav1.3 (a1D) L-type calcium
channel (LTCC) as the gatekeeper for the Zn wave. LTCC antagonists inhibited the Zn wave, and an agonist was sufficient to
induce it. Notably, a1D was mainly localized to the ER rather than the plasma membrane in mast cells, and the Zn wave was
impaired by a1D knockdown. We further found that the LTCC-mediated Zn wave positively controlled cytokine gene
induction by enhancing the DNA-binding activity of NF- kB. Consistent with this finding, LTCC antagonists inhibited the
cytokine-mediated delayed-type allergic reaction in mice without affecting the immediate-type allergic reaction. These
findings indicated that the LTCC a1D subunit located on the ER membrane has a novel function as a gatekeeper for the Zn
wave, which is involved in regulating NF-kB signaling and the delayed-type allergic reaction.
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Introduction
Zn is an essential trace element. Approximately 10% of all the
genes in the human genome may contain Zn-binding motifs [1],
and the dysregulation of Zn homeostasis is linked to a wide range
of physiological defects, including those affecting growth, devel-
opment, and the immune system [2,3].
Recent advances have revealed the existence and importance of
free or labile Zn in living organisms [4], and Zn has been
increasingly recognized as a potential biological signaling molecule
[5]. It is well established that synaptic Zn acts as a neurotrans-
mitter that can mediate cell–to-cell communication [6,7,8]. In
addition to such intercellular communication, Zn can act as a
second messenger [9], capable of transducing extracellular stimuli
into intracellular signaling events. Intracellular Zn signaling is
classified into two types: early and late [5,10,11]. Late Zn
signaling, which occurs several hours after extracellular stimula-
tion, depends on changes in the expression profile of Zn-related
molecules, such as Zn transporters and metallothioneins, and leads
to alterations in the intracellular Zn content and/or intracellular
distribution of Zn [12,13,14,15,16]. On the other hand, early Zn
signaling occurs several minutes after extracellular stimulation and
does not involve transcriptional changes. It is mediated by
extracellular Zn’s influx into the cytoplasm and by intracellular
Zn’s detachment from metalloproteins and release from intracel-
lular organelles.
FceRI stimulation induces a rapid elevation of the intracellular
free Zn level in mast cells, and we named this phenomenon the
‘‘Zn wave’’ [9]. The Zn wave originates in the perinuclear region,
which includes the endoplasmic reticulum (ER). Our evidence
suggests that it is positively involved in FceRI-mediated cytokine
production in mast cells. These findings indicated a novel function
for the Zn released from intracellular organelles as an intracellular
second messenger, like Ca
2+ [9]. However, the gatekeeper for the
Zn wave remained unknown.
In addition to the FceRI-mediated Zn wave in mast cells, the
rapid elevation of intracellular Zn by several stimuli for certain
cellular functions has been reported [17,18,19]. However, the
mechanism for the rapid intracellular induction of free Zn in those
studies, as well as in the case of the Zn wave, has remained
unclear.
L-type calcium channels (LTCCs) can conduct Zn [20] and act
as Zn-permeable channels on the plasma membrane of neurons
and pancreatic b cells [21,22]. However, it is unclear whether
LTCCs can also function in Zn’s release from intracellular organs.
The LTCCs are complexes that include a1, b, and a2/d subunits.
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ion-conducting pore [23], and a1 subunit on the cell surface is
proposed to require an association with the b subunit, which masks
one or more ER-retention signals [24,25]. Taken together, these
characteristics of LTCCs make them potential candidates for
performing the Zn wave gatekeeper function [21,22].
Transcription factors of the nuclear factor kB (NF-kB)/Rel
family play pivotal roles in inflammatory and immune responses
[26,27]. In unstimulated cells, NF-kB is sequestered in the
cytoplasm by its inhibitory proteins, the IkBs. Stimulants that
activate the NF-kB pathway induce the phosphorylation and
degradation of IkBs through the ubiquitin-proteasome pathway,
releasing NF-kB to enter the nucleus, where it binds specific DNA
sequences [28]. Mast cells secrete cytokines in response to antigen
stimulation and other activators [29,30]. NF-kB acts as a key
regulator for inflammatory cytokines such as IL-6 and TNF-a
[31]; in mast cells, FceRI stimulation induces the nuclear
translocation of NF-kB to increase these cytokines [32].
Redox regulation of NF-kB’s DNA-binding activity by Zn has
also been demonstrated; the mechanism involves Zn’s binding to
cysteine residues in the DNA-binding region of NF-kB, as shown
by site-directed mutagenesis experiments [33,34,35]. These
findings suggest that Zn is a signaling molecule that modulates
NF-kB, although the link between the regulation of NF-kB
activation and the Zn wave is unknown.
Here, we show that the pore-forming a1D subunit of LTCC on
the ER membrane plays a novel role in generating the Zn wave,
and that the NF-kB signaling pathway, a key regulator of allergic
responses, is one of the targets of the LTCC–mediated Zn wave in
mast cells.
Results
Expression of the LTCC a1D Subunit on the ER Membrane
in Mast Cells
LTCCs are Zn-permeable [20] and are expressed by various
cell types, including non-excitable cells [36]. To determine
whether this ion channel could be involved in the Zn wave in
mast cells, we examined the expression of the four pore-forming a1
subunits. RT-PCR analysis showed that cacna1d, the a1 subunit for
the Cav1.3 LTCC (a1D), was the dominantly expressed a1 subunit
in bone marrow-derived mast cells (BMMCs) (Figure 1A).
Furthermore, a1D protein was observed in BMMCs by western
blot analysis with an antibody against a1D; the signal was abolished
by prior incubation of the antibody with an antigenic peptide
(Figure 1B).
We next examined the intracellular distribution of the a1D in
BMMCs. In confocal microscopic analysis, the immunofluorescent
signal of a1D was observed in the intracellular area, partially
merged with that of the ER marker calnexin, but not with that of
F-actin, which accumulated beneath the plasma membrane
(Figure 1C). In addition, in a discontinuous sucrose density
gradient ultracentrifugation experiment, a1D was distributed in
fractions 4 and 5, which corresponded with fractions containing
the ER marker SERCA2 (fractions 3 to 5), but only partially
overlapped with fractions containing the plasma membrane
marker LAT (fractions 1 to 4) (Figure 1D). These results indicated
that a1D localized preferentially to intracellular organelle mem-
branes, such as the ER membrane, rather than to the plasma
membrane in mast cells.
The b subunit is known to be required for a1 subunits to be
localized to the plasma membrane and for their full activity as a
channel [24,25]. As shown in Figures 1E and F, the expression
levels of b subunits were very low in BMMCs, consistent with
a1D’s main localization to the ER in these cells. This intracellular
localization of a1D in BMMCs suggested that it plays a different
role from that observed in other cells, in which it is located on the
plasma membrane and acts as a calcium channel.
The LTCC a1D Subunit is a Gatekeeper for the Zn Wave in
Mast Cells
To examine whether LTCCs expressed on the ER membrane
are involved in the Zn wave, we examined the effect of the LTCC
antagonist Verapamil on the FceRI-induced Zn wave in BMMCs.
Verapamil-treated BMMCs showed an impaired Zn wave
compared to control cells (Figure 2A), without disturbing cell
survival or FceRI expression (Figures S1A and B). The FceRI-
mediated Ca
2+ elevation, however, was not inhibited by Verap-
amil in BMMCs (Figure 2B). The Zn wave was also inhibited in
BMMCs treated with a lower concentration of Verapamil (1 mM)
or with another type of LTCC antagonist, Diltiazem (Figures S2A
and B), and Diltiazem did not affect the FceRI-mediated Ca
2+
elevation (Figure S2C). On the other hand, treatment with the
LTCC agonist (s)-(-)-BayK8644, without antigen stimulation,
induced an elevation in the intracellular Zn level, but not in the
Ca
2+ level (Figures 2C, D, S3A, and B). The LTCC agonist-
induced increase in intracellular Zn was observed even in the
absence of Ca
2+, and it was inhibited by Verapamil (Figures 2C,
D, and S3C). To reveal whether the FceRI-induced Zn wave and
LTCC-mediated Zn elevation were regulated by a similar
mechanism, BMMCs were stimulated with antigen in the presence
of the LTCC agonist. The level of the FceRI-induced Zn elevation
was similar in BMMCs with or without the LTCC agonist,
indicating that the FceRI-induced Zn wave and LTCC agonist-
induced Zn elevation probably occur by a similar mechanism
(Figure S3D).
All these results were consistent with the idea that a1D, one of
the a1 subunits of LTCCs, might be a gatekeeper for the Zn wave
in mast cells. To examine this possibility further, we knocked down
a1D in BMMCs by siRNA. The expression level of the mRNA for
Cacna1d, but not for other Cacna1 family members, such as Cacna1f,
and the protein level of a1D were reduced in the a1D-knockdown
BMMCs compared with control cells (Figures S4). The FceRI-
induced Zn wave was significantly reduced in the a1D-knockdown
BMMCs compared with control cells (Figure 3A). On the other
hand, the a1D knockdown did not affect the FceRI-induced Ca
2+
elevation (Figure 3B), similar to the results of Verapamil treatment.
Moreover, the ectopic expression of wild-type a1D rescued the
inhibitory effect of siRNA knockdown on the Zn wave (Figure 3C).
These results indicated that the LTCC a1D subunit is a gatekeeper
for the Zn wave.
Requirement of the Zn Wave for FceRI-induced Cytokine
Gene Induction, but not for Degranulation in Mast Cells
FceRI stimulation activates several downstream pathways that
initiate immediate allergic inflammatory responses by eliciting
mast-cell degranulation, accompanied by the rapid release of
preformed chemical mediators, such as histamine and serotonin.
In contrast, the mast cell–mediated delayed-type responses are
mainly dependent on cytokine production. To examine whether
the LTCC-mediated Zn wave could play a role in these mast-cell-
activation events, we first investigated the effect of Verapamil
treatment and a1D knockdown on FceRI-mediated cytokine gene
induction and degranulation. Inhibition of the Zn wave by
Verapamil reduced the FceRI-mediated gene induction of Il6 and
Tnfa in BMMCs (Figure 4A). The a1D-knockdown BMMCs also
showed impaired FceRI-mediated gene induction of Il6 and Tnfa
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expression level in the a1D-knockdown BMMCs was 20.567.1%
of the control level. On the other hand, neither Verapamil
treatment nor a1D knockdown inhibited the FceRI-mediated
degranulation in these cells (Figures 4C and D). Taken together,
these results indicated that the Zn wave is involved in the FceRI-
mediated cytokine gene induction, but not the degranulation, of
mast cells.
Role of the Zn Wave in the NF-kB Pathway
Since NF-kB is a master transcription factor that controls the
expression of proinflammatory cytokines such as IL-6 and TNF-a
in mast cells [37], the Zn wave was likely to be involved in the
FceRI-induced NF-kB-signaling pathway. Inhibiting the Zn wave
with Verapamil did not affect FceRI-induced IKK phosphoryla-
tion, IkB phosphorylation, or its degradation in BMMCs
(Figure 5A). Even though the upstream activation pathway of
NF-kB was intact, the frequency of NF-kB p65 accumulation in
the nuclei upon FceRI stimulation was reduced in the Verapamil-
treated BMMCs (Figure 5B). These results indicated that the Zn
Figure 1. The a1D subunit of LTCC is primarily expressed on the ER membrane in mast cells. (A) RT-PCR of mRNA encoding the a1 subunit
of LTCC family members (cacna1s, cacna1c, cacna1d, and cacna1f), and Gapdh in BMMCs. (B) Western blot for a1D in BMMCs. Total cell lysates were
blotted with an anti-a1D polyclonal antibody or the same antibody pre-incubated with an antigenic peptide. Arrowhead indicates the putative a1D
signal; this signal detected by the antibody pre-incubated with antigenic peptide was 15.1611.1% of that detected by the anti-a1D polyclonal
antibody. (C) Intracellular distribution of the LTCC a1D subunit in BMMCs examined by confocal microscopy. Representative images are shown.
Staining with an anti-a1D monoclonal antibody is in green, anti-Calnexin (ER marker) in red, or phalloidin-Alexa 546 (for F-actin beneath the plasma
membrane) in red, and 49 6-diamidino-2-phenylindole, dihydrochloride (DAPI; for nuclei) in blue. (D) The postnuclear supernatant obtained from
BMMCs was fractionated by ultracentrifugation in a discontinuous sucrose gradient. The collected fractions were then separated by SDS-PAGE, and
the protein distributions were detected by immunoblotting with antibodies against a1D, SERCA2 (ER), and LAT (plasma membrane). (E) The mRNA
expression of LTCC b-subunit family members (cacnb1t ocacnb4) in the brain and BMMCs was examined by RT-PCR. (F) The protein levels of the b2
and b4 subunits in the brain and BMMCs were examined by western blots.
doi:10.1371/journal.pone.0039654.g001
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for its upstream activation pathway. We further investigated
whether the Zn wave was required for the nuclear import step. For
this, we used the exportin inhibitor leptomycin B (LMB). The
frequency of NF-kB in nuclei was elevated by LMB treatment, and
this effect was observed even in the presence of Verapamil (Figure
S5A), suggesting that the Zn wave might be required for post
nuclear translocation events, rather than for the nuclear import
step.
Therefore, we next examined the DNA-binding activity of NF-
kB p65 in nuclei. Whereas the DNA-binding activity of NF-kBi n
nuclei was elevated after FceRI stimulation in BMMCs, it was
reduced in Verapamil-treated cells. This reduction in DNA-
binding activity was recovered by adding Zn with the FceRI
stimulation (Figure 5C). Consistent with this result, the reduction
in FceRI-mediated cytokine gene induction in Verapamil-treated
BMMCs was recovered by Zn supplementation (Figure 5D). These
results indicated that the Zn wave might participate in the signal
transduction for cytokine gene induction by enhancing the DNA-
binding activity of NF-kB.
Role of the Zn Wave in the Regulation of Allergic
Responses in vivo
Mast cells are a major player in allergic responses such as the
immediate- and delayed-type hypersensitivity reactions [30].
Passive cutaneous anaphylaxis (PCA) and contact hypersensitivity
(CHS) are mouse models for the immediate-type and delayed-type
allergic responses, respectively. We therefore examined the effect
of Verapamil treatment on the PCA and CHS reactions. The
allergic response in the PCA model was evaluated by the
Figure 2. LTCC is involved in regulation of the Zn wave. (A) The intracellular labile Zn level after FceRI-mediated stimulation was examined
using the fluorescent Zn indicator Newport Green in mast cells with or without pre-treatment with 100 mM Verapamil, an LTCC antagonist. The data
represent the relative fluorescent intensity of Newport Green. The difference in Newport Green intensity at 15 min between the control and
Verapamil-treated BMMCs was statistically significant. *P,0.05, Student’s t-test. (B) The FceRI-mediated Ca
2+ elevation in control and Verapamil-
treated BMMCs was examined using the fluorescent Ca
2+ indicator Fluo-4. Data represent the relative fluorescent intensity of Fluo-4. The difference in
Fluo-4 intensity between the control and Verapamil-treated BMMCs was not statistically significant. (C) The intracellular labile Zn level upon
treatment with the LTCC agonist (s)-(-)-BayK8644 in BMMCs with or without 100 mM Verapamil. The difference in Newport Green intensity at 15 min
between the control and Verapamil-treated BMMCs was statistically significant. ***P,0.001. (D) The intracellular labile Zn level upon (s)-(-)-BayK8644
treatment of BMMCs in control or Ca
2+-free Tyrode’s buffer. The difference in Fluo-4 intensity between the control and Ca
2+-free Tyrode’s buffer
samples was not statistically significant. All data are representative of at least three experiments, and are shown as the mean + SEM. NPG, Newport
Green; Vera, Verapamil; Bay, (s)-(-)-BayK8644.
doi:10.1371/journal.pone.0039654.g002
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sensitized and challenged with an antigen. There was no notable
difference in the extravasation of Evans blue dye in the ear of the
vehicle-versus Verapamil-treated mice (Figure 6A), indicating that
the mast cell–mediated PCA reaction occurred normally in the
presence of Verapamil.
We then examined the CHS response to the experimental
hapten FITC, by assessing the amount of tissue swelling at the
site of hapten challenge. While the vehicle-treated mice
developed a robust CHS response 24 h after stimulation, the
Verapamil-treated mice showed a greatly reduced response
(Figure 6B). In addition, mice treated with the other LTCC
antagonist, Diltiazem, showed a decreased FITC-induced CHS
response (Figure S6). The effects of Verapamil on mast-cell
activation in vitro (Figure 4) and the allergic response in vivo
together indicated that the Zn wave plays a role in FceRI-
induced cytokine production, but not in degranulation, and is
involved in regulating the delayed-type but not the immediate–
type allergic response.
Discussion
Identification of the LTCC a1D Subunit as a Gatekeeper
for the Zn Wave
It is well established that LTCCs function as voltage-gated
calcium channels on the plasma membrane. In this study, we
showed that the LTCC a1D subunit was expressed in mast cells,
but was localized to the ER rather than to the plasma membrane.
We also showed that the expression level of LTCC b subunits,
which are required for the localization of a1 subunits to the plasma
membrane [24,25], was very low in mast cells. Furthermore, the
expression of ZnT-1 in mast cells [16] might support the ER
Figure 3. Effect of a1D knockdown on the FceRI-mediated Zn wave. (A) The intracellular labile Zn level upon antigen stimulation was
examined in control and a1D siRNA-treated BMMCs. The difference in Newport Green intensity at 15 min between the control and a1D siRNA-treated
BMMCs was statistically significant. *P,0.05, Student’s t-test. (B) The intracellular Ca
2+ level upon antigen stimulation was examined in control and
a1D siRNA-treated BMMCs. The difference in Fluo-4 intensity between the control and a1D siRNA-treated BMMCs was not statistically significant. (C)
The FceRI-mediated Zn wave was examined in a1D siRNA-treated BMMCs with or without transfection of human a1D. All data represent the mean +
SEM. N.S., not significant, *P,0.05, ***P,0.001, Bonferroni’s multiple comparison test. NPG, Newport Green.
doi:10.1371/journal.pone.0039654.g003
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transcription upon antigen stimulation for the indicated time in BMMCs with or without pretreatment with 100 mM Verapamil were determined by
semi-quantitative RT-PCR. (B) The mRNA levels of Il6 and Tnfa upon antigen stimulation for 60 min in control (siControl) or a1D siRNA-treated (si a1D)
BMMCs were determined by semi-quantitative RT-PCR. (C) The level of degranulation after 30 min of antigen stimulation in BMMCs with or without
pretreatment with 100 mM Verapamil was determined by measuring the b-hexosaminidase activity. (D) Level of degranulation after 30 min of antigen
stimulation in siControl and a1D siRNA-treated BMMCs. N.S., not significant, *P,0.05, **P,0.01, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0039654.g004
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with b subunits on the plasma membrane, reducing their
availability to bind a1, and thus inhibiting a1-subunit trafficking
to the plasma membrane [38].
An important finding in the present study was that the a1D
subunit expressed on the ER membrane has little effect on FceRI-
induced Ca
2+ influx, and instead plays a novel role as a gatekeeper
for the Zn wave. Our data showed that LTCC antagonist
Figure 5. Possible involvement of the Zn wave in regulating the DNA-binding activity of p65 NF-kB. (A) IKKa/b phosphorylation and
IkBa phosphorylation and degradation. After antigen stimulation, cells were lysed, and the cytosol fraction was immunoblotted with anti-phospho-
IkBa or anti-phospho-IKKa/b antibodies. Results were normalized to the non-phosphorylated IkBa and IKKa. (B) NF-kB nuclear translocation
visualized by confocal microscopy. BMMCs were untreated or treated with Verapamil and stimulated with antigen for 15 min. Cells were stained with
anti-p65 (green) and DAPI (blue). Scale bar, 10 mm. The frequency of NF-kB nuclear-translocated cells was calculated. Values are means + S.D.
*P,0.05, two-tailed Student’s t-test. (C) DNA-binding activity was calculated by dividing the amount of p65 bound to target DNA by the total p65 in
the nuclear fraction. BMMCs were untreated or pre-treated with Verapamil, then stimulated with antigen for 15 min. For Zn supplementation, 1 mM
Zn and pyrithione were added with the antigen stimulation. (D) BMMCs were untreated or treated with Verapamil, and stimulated with antigen for
60 min. Zn supplementation was as in (C). The Il6 and Tnfa mRNA levels were determined by semi-quantitative RT-PCR. Data show means + S.D. N.S.,
not significant, *P,0.05, **P,0.01, ***P,0.001, Bonferroni’s multiple comparison test.
doi:10.1371/journal.pone.0039654.g005
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affect the FceRI-mediated Ca
2+ elevation or FceRI-mediated
degranulation, which requires an increase in intracellular Ca
2+.I n
addition to the lack of effect on FceRI-mediated Ca
2+ elevation,
Ca
2+-mediated signaling was not disturbed in the Verapamil-
treated BMMCs, as shown by the normal nuclear translocation of
NFAT2 in these cells (Figure S7). In addition, LTCC agonist
treatment increased the level of intracellular free Zn but not of
Ca
2+ in mast cells. These results showed that LTCC is not
involved in the FceRI-mediated Ca
2+ regulation in mast cells. This
might be because mast cells, like lymphocytes, utilize store-
operated calcium (SOC) entry as their main mode of Ca
2+ influx
[39]. However, we could not rule out the ability of a1D subunit
expressed on the ER membrane to conduct Ca
2+ from the ER to
the cytoplasm.
Most importantly, our finding that the LTCC a1D subunit,
when expressed on the ER membrane, has a novel function as a
gatekeeper for the Zn wave also made it possible for us to address
the physiological roles of the Zn wave.
Regulation of the LTCC Activation for Zn Wave
Generation
The a1 subunits of LTCC contain a voltage-sensor domain, and
the channel activity is elevated after membrane depolarization.
The plasma membrane potential in BMMCs is hyperpolarized
after FceRI stimulation [40,41], but we found that inhibition of the
FceRI-mediated plasma membrane hyperpolarization by high
KCl treatment did not impair induction of the Zn wave (Figures
S8A and B). We then examined the intracellular membrane
potential using tetramethyl rhodamine methyl ester (TMRM).
Treatment with the ADP/ATP transporter inhibitor bongkrekic
acid inhibited the FceRI-mediated intracellular membrane depo-
larization, but it did not inhibit the induction of the Zn wave
(Figures S8C and D). This result suggested that intracellular
membrane depolarization does not affect the Zn wave generation,
although we cannot exclude the possibility that depolarization of
the ER inner membrane has an effect.
Modification of the pore-forming a1 subunit by phosphorylation
has an additional effect on channel activity; in fact, cAMP-
mediated channel activity is reduced by site-directed mutagenesis
of the PKA consensus sites of a1D [42]. However, we did not
observe a negative effect on the Zn wave by PKA inhibitor
treatment (Figure S9); therefore, PKA may not participate in the
regulation of the Zn wave, at least in mast cells. As-yet unidentified
regulatory proteins on the ER membrane may control this event.
Zn Wave Regulates the DNA-binding Activity of NF-kB
and Cytokine Gene Induction
We found that the LTCC-mediated intracellular Zn signal
upregulates the DNA-binding activity of NF-kB and the
transactivation of inflammatory cytokines. NF-kB-mediated trans-
activation can be divided into the following three steps. First, NF-
kB dissociates from IkB after IkB’s phosphorylation and
degradation. Second, NF-kB translocates from the cytosol to the
nucleus, and finally, NF-kB binds to its target sequences. We
found that the frequency of NF-kB p65 nuclear translocation was
reduced in LTCC antagonist-treated cells, even though the
upstream regulators were unaffected. Treatment with the exportin
inhibitor LMB enhanced the frequency of NF-kB in nuclei, and
this effect was observed in LTCC antagonist- and LMB-treated
cells, suggesting that the Zn wave is not involved in the nuclear
translocation step. Rather, our evidence indicates that the Zn wave
is required for the DNA-binding activity of NF-kB.
That the LTCC antagonist treatment reduced the DNA-
binding activity of NF-kB further supports this scenario. More-
over, the DNA-binding activity of NF-kB was enhanced by
supplementing the cell lysate with Zn (Figure S5B). These findings
suggest that the elevated intracellular Zn caused by the Zn wave
positively regulates the DNA-binding activity of NF-kB. However,
although we showed that the Zn wave is involved in FceRI-
Figure 6. Effect of Verapamil treatment on allergic responses in vivo. (A) Analysis of passive cutaneous anaphylaxis, an immediate-type
allergy response. Vehicle- or Verapamil-treated mice received intradermal injections of IgE anti-DNP into the right ear and saline into the left (control).
Data show the amount of Evans blue extravasation into the ears. (n=8 per group, from two independent experiments). N.S., not significant. (B)
Analysis of contact hypersensitivity, a delayed-type allergic response. Vehicle- or Verapamil-treated mice were sensitized with FITC, and ear swelling
was measured at the indicated times after hapten challenge. Data show means + SEM. (n=5 per group, experiment performed three times).
**P,0.01, ***P,0.001, two-tailed Student’s t-test.
doi:10.1371/journal.pone.0039654.g006
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which induced an increase in free zinc, like the Zn wave, did not
increase the mRNA induction and protein synthesis of IL-6 and
TNF-a (Figure S10). These results suggest that the Zn wave is
required, but not sufficient, for the FceRI-induced cytokine
productions in mast cells. Nevertheless, taken together, our results
indicate that the Zn wave is a novel modulator of NF-kB
activation.
The Zn Wave is Involved in the Delayed-type Allergic
Response in vivo
The mast cell is one of the effector cells for allergic responses
in vivo. Mast cell-derived cytokines, which are induced by FceRI-
mediated activation of the PKC/Bcl10/Malt1/NF-kB signaling
pathway, are known to be involved in delayed-type allergic
responses, such as CHS [16,43]. Mast cell-derived TNF is
required for the maximum CHS response; it induces the
infiltration of leukocytes at the site of inflammation [44], enhances
the elongation of cutaneous nerves [45], and enhances the
dendritic cell migration to draining lymph nodes [46]. In this
study, we revealed that treating mice with the LTCC antagonist
Verapamil inhibited the CHS reaction, a delayed-type immune
response, without affecting the PCA, an immediate-type response.
Consistent with these results, we showed that Verapamil treatment
inhibited the FceRI-mediated activation of NF-kB’s DNA-binding
activity and cytokine gene inductions, but not Ca
2+ elevation or
degranulation in BMMCs. Thus, the inhibitory effect of Verap-
amil on CHS might depend at least in part on the reduction of
mast cell-derived cytokine production, independent of other
mediators, such as histamine. Although we do not exclude the
possibility that Verapamil affects the function of dendritic cells and
T cells in vivo, all our results suggest that one of the in vivo roles of
the Zn wave is to regulate the allergic response by controlling
cytokine production in mast cells.
In summary, we identified a novel function of the pore-forming
a1D subunit of LTCC, when it is expressed on the ER membrane,
as the gatekeeper for the Zn wave in mast cells. In addition, the
LTCC-mediated Zn wave may function as a positive regulator for
inflammatory cytokines by enhancing NF-kB’s DNA-binding
activity. These findings will help us understand the regulation
and importance of intracellular Zn signaling in a variety of
biological responses in which Zn-susceptible proteins are involved.
Materials and Methods
Cell Culture and Mice
All animal experiments were conducted in accordance with
animal protocols approved by the Animal Research Committee at
RIKEN (permit number 22-013(3)). Bone marrow-derived mast
cells (BMMCs) were prepared as described previously [47]. Briefly,
8-week-old C57/BL6 mice were sacrificed, and their bone-
marrow cells were cultured in RPMI 1640 supplemented with
10% FCS, 10 mU/mL penicillin, 0.1 mg/mL streptomycin,
40 mM 2-ME, and IL-3, in a 5% CO2 and 95% humidified
atmosphere at 37uC. After 4–5 weeks of culture, the cell-surface
expression of FceRI and c-Kit was confirmed, and the cells were
used for experiments.
Reagents and Antibodies
Newport Green DCF diacetate, Fluo-4 AM, 49,6-diamidino-2-
phenylidole, dihydrochloride (DAPI), bis-(1,3-dibutylbarbituric
acid) trimethine oxonol (DiBAC4(3)), and tetramethyl rhodamine
methyl ester perchlorate (TMRM) were from Molecular Probes.
Anti-Flag (M2) and anti-b-tubulin were from Sigma, anti-Cav1.3
polyclonal antibody was from Alomone Labs, anti-Cav1.3
monoclonal antibody L48A/9 was from NeuroMab, anti-
GM130 was from BD Transduction Laboratories, anti-SERCA2
was from Abcam, anti-NF-kB p65 was from Santa Cruz
Biotechnology, anti-LAT was from Upstate, and anti-phospho
IKKa/b, anti-IKKa, anti-IkBa, and anti-phospho IkBa were
from Cell Signaling. The siRNAs for control (siGENOME Non-
Targeting siRNA Pool #1) and mouse Cacna1d (siGENOME
SMARTpool, Mouse CACNA1D (12289)) were purchased from
Thermo Fisher Scientific.
Plasmid Construction and Transfection
The coding region of the human CACNA1D gene was isolated
from a cDNA library of human brain (Clontech). To construct N-
terminally FLAG-tagged CACNA1D, the CACNA1D fragment was
amplified by PCR, followed by sequencing and cloning into the
NotI and XbaI site of the expression vector p3XFLAG-Myc-
CMV26 (Sigma Aldrich). BMMCs were transfected with expres-
sion vectors or siRNA using a two-step electroporator CUY21Pro-
Vitro (Nepa Gene, Japan). For the electroporation, 1610
6
BMMCs were resuspended in 100 ml of OPTI-MEM, and 10 mg
of plasmid DNA or 400 pmol of siRNA was added. Electropo-
ration was carried out with 1 pore-forming pulse (275 V for
3 msec) and 10 driving pulses (20 V for 50 msec), and then the
BMMCs were diluted in 1 ml of BMMC culture medium. After a
48-h incubation, the cells were used for experiments.
RT-PCR and Real-time Quantitative RT-PCR Analyses
Total RNA was extracted and reverse-transcribed as previously
described [32]. For standard RT-PCR, each sample was subjected
to PCR with sense and antisense primers: cacna1s,5 9-
TGTGGTATGTCGTCACTTCCTCC (sense) and 59-
CGTCAATGATGCTGCCGATG (antisense); cacna1c,5 9-
CAAGCCCTCACAAAGGAATGC (sense) and 59-
AAAGTTGCCCCTGCTGTCACTC; cacna1d,5 9-ATCTCACA-
CACCGCCAGGACTATG (sense) and 59-CATCACCTTT-
GACCTCTCTCGTG (antisense); cacna1f,5 9-AAGATTTACC-
TATCCCAGGCACCTAC (sense) and 59-
CATCAAAGCGGGAAAGAATAGACTC (antisense). For real-
time quantitative RT-PCR, the IL-6 and TNF-a gene expressions
were measured relative to GAPDH using SYBR
H Green (Applied
Biosystems). The primers used in these experiments were as
follows: IL-6, 59- GAGGATACCACTCCCAACAGACC (sense)
and 59- AAGTGCATCATCGTTGTTCATACA (antisense);
TNF-a,5 9- CATCTTCTCAAAATTCGAGTGACAA (sense)
and reverse primer, 59- TGGGAGTAGACAAGGTACAACCC
(antisense); GAPDH, 59- TTCACCACCATGGAGAAGGCCG
(sense) and 59- GGCATGGACTGTGGTCATGA (antisense).
The primer pairs used to detect Cacna1 family members were the
Perfect Real Time Primer (Takara Bio Inc, Japan) for the Mus
musculus calcium channel, voltage-dependent, alpha 1S subunit
(Cacna1s), transcript variant 2 mRNA (Position 5019), M. musculus
alpha 1C subunit (Cacna1c) mRNA (Position 5787), M. musculus
alpha 1D subunit (Cacna1d), transcript variant 2 mRNA (Position
6650), and M. musculus alpha 1F subunit (Cacna1f) mRNA
(Position 5601).
Cell Lysates and Immunoblotting
BMMCs were harvested, lysed with lysis buffer (20 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1% NP-40, proteinase inhibitors,
5 mg/ml pepstatin, 10 mg/ml leupeptin) for 30 min at 4uC, and
spun at 12,0006g, 4uC, for 30 min. The eluted and reduced
samples were resolved by SDS-PAGE using a 4–20% gradient
polyacrylamide gel (Wako), and transferred to a PVDF membrane
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were incubated with the primary antibodies anti-Cav1.3 (1:500),
anti-LAT (1:1000), anti-SERCA2 (1:1000), anti-phospho IkBa
(1:2000), anti-IkBa (1:1000), anti-b-tubulin (1:5000), anti-phospho
IKKa/b (1:1000), or anti-IKKa (1:500) antibodies. The mem-
branes were then incubated with HRP-conjugated anti-mouse,
rabbit, or goat IgG (Zymed) for 1 h at room temperature. After
extensive washing of the membranes, immunoreactive proteins
were visualized using the Western Lightning-ECL system,
according to the manufacturer’s recommendation. The PVDF
membranes were exposed to Fuji RX film (Fuji). Densitometric
analysis was performed using an LAS-1000 fluorescence image
analyzer (Fujifilm).
Microscopy
The intracellular Zn or Ca
2+ level was measured as described
previously [9]. Briefly, sensitized BMMCs were allowed to adhere
to a poly-L-lysine-coated glass-bottom dish or glass-bottom dish.
After being incubated with 10 mM Newport Green or 5 mM Fluo-
4 for 30 min at 37uC, the cells were stimulated with 100 ng/ml
dinitrophenylated human serum albumin (DNP-HSA; Sigma) or
10 mM (s)-(-)-BayK8644 at 37uC. The images of fluorescent signals
were captured every 10 or 30 sec with an inverted microscope
(Axiovert 200 MOT, Carl Zeiss), CCD camera (Cool Snap HQ,
Roper Scientific), and the system control application SlideBook
(Intelligent Imaging Innovation).
For the immunostaining of BMMCs, the cells on a poly-L-lysine
coated dish were fixed with 4% paraformaldehyde for 10 min at
37uC, then permeabilized in Perm Buffer (BD) containing 1% BSA
for 15 min at room temperature. Primary and secondary staining
were performed on the poly-L-lysine coated dish: anti-Cav1.3 at a
dilution of 1:50, anti-SERCA2 at 1:100, anti-p65 at 1:50,
Alexa488-conjugated anti-rabbit IgG, (Molecular Probes), Phal-
loidin-Rhodamine (Molecular Probes) at 1:100, and DAPI at
1:5000. Confocal microscopy was carried out using the TCS SL
system (Leica). Images were transferred to Adobe Photoshop CS3.
Sucrose Gradient Fractionation Assay
Mature BMMCs (5610
7) were harvested and washed with PBS
and homogenized with a Dounce homogenizer in 0.5 ml of ice-
chilled HES buffer (250 mM sucrose, 1 mM EDTA, 20 mM
HEPES, pH 7.5). The homogenate was spun at 5006g for 5 min
to sediment the nuclei, and the postnuclear supernatant was used
for further fractionation. The postnuclear supernatant was mixed
with 0.5 ml of 0.8 M sucrose in 50 mM Tris-HCl and loaded onto
the top of a discontinuous sucrose gradient (0.6, 1, 1.35, 1.65, 2 M)
prepared in the same buffer. The gradient was spun in a SW 55 Ti
rotor for 16 h at 100,0006g (32,100 rpm) in a Beckman
ultracentrifuge, and fractions of 300 ml each were collected from
the top of the tube. Proteins from each fraction were separated by
SDS-PAGE.
Measurement of Cytokines
Cells were sensitized with 1 mg/mL IgE for 6 h at 37uC. After
sensitization, the cells were washed twice with Tyrode’s buffer
(10 mM HEPES pH 7.4, 130 mM NaCl, 5 mM KCl, 1.4 mM
CaCl2, 1 mM MgCl2, 5.6 mM glucose), then suspended in the
same buffer containing 0.1% BSA and stimulated with polyvalent
dinitrophenyl-human serum albumin (DNP-HSA, Sigma) for
30 min. TNF-a and IL-6 in the cell culture supernatants were
measured with an ELISA kit (Biosource), following the manufac-
turer’s recommendation.
BMMC Degranulation Assay
Cells were activated as described above, then spun down at
60006g for 1 min, and 50 ml of the culture supernatant or the cell
pellet solubilized with 1% Triton X-100 in Tyrode’s buffer was
combined with 100 mL of 1.3 mg/mL p-nitrophenyl-N-acetyl-D-
glucosamide and developed for 60 min at 37uC. The enzyme
reaction was stopped by adding 150 mL of 0.2 M glycine-NaOH
(pH 10.2), and the absorbance at 405 nm was measured with a
microplate reader (Bio-Rad).
FITC-induced Contact Hypersensitivity
The FITC-induced CHS procedure was performed as described
previously [46]. Briefly, mice were sensitized by applying 200 mlo f
2% FITC isomer-I (FITC; Sigma-Aldrich) in a vehicle consisting
of acetone-dibutylphthalate (1:1) to the skin of the back. Five days
after the sensitization with FITC, the mice were pretreated with
20 ml of acetone-EtOH (1:1) or 50 mg/ml Verapamil in acetone-
EtOH (1:1) and then challenged with 20 ml of vehicle alone on the
right ear (10 ml on each side of the ear) and 1% FITC on the left
ear (10 ml on each side). The ear thickness was measured before
and at various times after FITC challenge, with an engineer’s
microcaliper (Ozaki).
Passive Cutaneous Anaphylaxis
A total of 2 mg IgE in 20 ml was injected subcutaneously into the
ears over a period of 12 h. After the sensitization, the mice were
challenged with an intravenous injection of 50 ml polyvalent
dinitrophenyl-bovine serum albumin (DNP-BSA: Cosmobio,
Japan) in 250 ml of saline-5 mg/mL Evans blue dye (Sigma,
Japan). The extravasation of Evans blue into the ear was
monitored for 30 min. The mice were then sacrificed, both ears
were dissected, and the Evans blue dye was extracted in 700 mlo f
formamide at 63uC overnight. The absorbance of the Evans blue-
containing formamide was measured at 620 nm.
NF-kB DNA-binding Assay
The DNA-binding activity of NF-kB p65 was examined with
the TransAM
TM NFkB p65 kit (Active Motifs), according to the
manufacturer’s protocol. In brief, sensitized BMMCs (2610
6) were
rinsed twice with Tyrode’s buffer and incubated with or without
100 mM Verapamil for 30 min at 37uC, then stimulated with
10 ng/ml DNP-HSA for 30 min at 37uC with or without 1 mM
pyrithione and ZnSO4. The cytosolic and nuclear proteins were
separated using the Nuclear Extraction Kit (TransAM) according
to the manufacturer’s protocol. Nuclear proteins were prepared in
a5 0ml volume, and 20 ml of each sample was used to estimate the
amount of DNA-bound NF-kB p65, and 15 ml of each sample was
subjected to SDS-PAGE to determine the total amount of NF-kB
protein in the nuclear fraction. The DNA-binding activity of the
NF-kB p65 in the nuclear fraction was estimated by dividing
the amount of NF-kB p65 bound to the target sequence by the
amount of NF-kB p65 protein in the nuclear fraction.
Statistical Analysis
All statistical analyses were performed using Statcel software.
Data were analyzed by two-tailed Student’s t-test or Student’s t-
test with Bonferroni’s correction for multiple comparison. Data
were considered statistically significant when the P value was less
than 0.05. N.S., not significant, *P,0.05, **P,0.01, ***P,0.001.
Supporting Information
Figure S1 Effect of the LTCC antagonist Verapamil on
cell survival and the surface expression of receptors. (A)
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concentrations of Verapamil was determined by flow cytometry.
Cell viability was detected by staining BMMCs with 7-AAD.
Numbers show the percentage of total cells that were 7-AAD-
positive dead cells. Zn toxicity-induced cell death was observed as
a control by treating the cells with 1 mM pyrithione and 10 mM
ZnSO4 for 3 h. (B) The surface expression levels of c-kit and FceRI
were examined in BMMCs that were untreated or treated with 50
or 100 mM Verapamil for 3 h.
(TIF)
Figure S2 LTCC antagonists inhibit the FceRI-mediated
Zn wave. (A) The intracellular labile Zn level after FceRI-
mediated stimulation was examined using the fluorescent Zn
indicator Newport Green in mast cells with or without pre-
treatment with 1 mM Verapamil. The data represent the relative
fluorescent intensity of Newport Green, means + SEM. The
difference in Newport Green intensity at 15 min between the
control and Verapamil-treated BMMCs was statistically signifi-
cant. *P,0.05, Student’s t-test. (B) The intracellular labile Zn level
after FceRI-mediated stimulation was examined in mast cells with
or without pre-treatment with 100 mM( +)-cis-Diltiazem hydro-
chloride (Sigma Aldrich). The data represent the relative
fluorescent intensity of Newport Green, means + SEM. The
difference in Newport Green intensity at 15 min between the
control and Diltiazem-treated BMMCs was statistically significant.
*P,0.05. (C) The FceRI-mediated Ca
2+ elevation in control and
Diltiazem-treated BMMCs was examined using the fluorescent
Ca
2+ indicator Fluo-4. Data represent the relative fluorescent
intensity of Fluo-4, means + SEM. The difference in Fluo-4
intensity between the control and Diltiazem-treated BMMCs was
not statistically significant, Student’s t-test. All data are represen-
tative of at least three experiments.
(TIF)
Figure S3 An LTCC agonist can induce the Zn wave
without antigen stimulation. (A) Time-lapse recording of the
Newport Green signal in BMMCs treated with 10 mM (s)-(-)-
BayK8644, an LTCC agonist. Images were converted into
pseudocolors, in which low intensity is blue and high intensity is
red. (B) The intracellular Ca
2+ elevation upon agonist treatment
was examined using the fluorescent Ca
2+ indicator Fluo-4. After
10 min of (s)-(-)-BayK8644 treatment, 1 mM ionomycin, a Ca
2+
ionophore, was added to the buffer and the intracellular Ca
2+ was
further examined for 150 seconds. (C) The intracellular Zn level in
BMMCs treated with the indicated concentrations of (s)-(-)-
BayK8644 for 15 min in control or Ca
2+-free Tyrode’s buffer
was determined by flow cytometry. (D) The intracellular Zn level
in BMMCs with or without (s)-(-)-BayK8644 treatment along with
antigen stimulation was determined by flow cytometry. BMMCs
were stimulated with 100 ng/ml DNP-HSA and 5 mM (s)-(-)-
BayK8644 for 15 min. NPG, Newport Green; Bay, (s)-(-)-
BayK8644.
(TIF)
Figure S4 Introduction of siRNA for a1D into BMMCs.
(A) The mRNA levels of Cacna1s were determined by semi-
quantitative RT-PCR in control (siControl) or a1D siRNA-treated
(si a1D) BMMCs. Under our experimental conditions, Cacna1s and
Cacna1c were below the detection level. The mRNA level in si
a1D–treated BMMCs was 24.565.2% (for Cacna1d) and
98.6612.8% (for Cacna1f) of that in control cells. Data are
representative of three independent experiments. (B) The protein
level of a1D was examined in control and a1D siRNA-treated
BMMCs. Arrowhead indicates the putative a1D signal. The
protein level in si a1D–treated BMMCs was 32.6610.5% of that in
control cells.
(TIF)
Figure S5 Effectofanexportininhibitorontheinhibition
of nuclear translocation by an LTCC antagonist. (A) The
frequency of NF-kB nuclear-translocated cells was determined by
confocal microscopy. BMMCs were pretreated with 20 ng/ml
leptomycinBfor2 h,and100 mMVerapamil,anLTCCantagonist,
for 30 min,then stimulatedwith100 ng/mlDNP-HSAfor 15 min.
(B) ZnSO4 at the indicated concentration was added to the
cytoplasmic compartment of BMMCs for 30 min, and then the
DNA-binding activity ofNF-kBwas determined.
(TIF)
Figure S6 Effect of Diltiazem on allergic responses in
vivo. Analysis of the effect of Diltiazem on contact hypersensi-
tivity. Vehicle-, Verapamil-, or Diltiazem-treated mice were
sensitized with FITC, and ear swelling was measured at the
indicated times after hapten challenge. Data represent means +
S.E.M. (n=6 for vehicle, n=4 for Verapamil, and n=5 for
Diltiazem from two independently performed experiments).
*P,0.05, Bonferroni’s multiple comparison test.
(TIF)
Figure S7 Effect of Verapamil on FceRI-mediated Ca
2+
signaling. NFAT2 nuclear translocation was visualized by
confocal microscopy. BMMCs were untreated or treated with
Verapamil and stimulated with antigen for 30 min. The frequency
of NFAT2 nuclear-translocated cells was determined. Data
represent the means + S.D. N.S., not significant, Bonferroni’s
multiple comparison test.
(TIF)
Figure S8 Effect of membrane potential changes on Zn-
wave generation. (A) The plasma membrane potential was
determined using a membrane potential-sensitive fluorescent dye
DiBAC4(3)andflowcytometry.Datarepresentthemeanfluorescent
intensityofDiBAC4(3).(B)TheeffectofahighconcentrationofKCl
on the FceRI-mediated Zn wave was determined by examining the
intracellular labile Zn level with or without 50 mM KCl treatment.
Data represent the relative fluorescent intensity of Newport Green.
(C) The intracellular membrane potential was determined with the
cationicdyeTMRM.BMMCsweretreatedwith20 mMBongkrekic
acidfor30 minbeforestimulation.TheTMRMintensityofantigen-
stimulated cells was determined by flow cytometry. Data represent
therelativefluorescentintensityofTMRM.(D)TheintracellularZn
levelofBMMCstreatedwithorwithout20 mMBongkrekicacidupon
antigen stimulation was determined by flow cytometry. Data
represent the relative fluorescent intensity of Newport Green. N.S.,
not significant, *P,0.05, **P,0.01. Ag, Antigen; NPG, Newport
Green.
(TIF)
Figure S9 Effect of PKA-mediated signaling on the
FceRI-induced Zn wave. The FceRI-mediated Zn wave was
examined in BMMCs treated with a PKA inhibitor at the
indicated concentration. The intracellular labile Zn level was
determined by staining the BMMCs with Newport Green and
analyzed by flow cytometry. Data represent the mean fluorescent
intensity of Newport Green 6 S.D. ***P,0.001 Student’s t-test,
two-tailed. NPG, Newport Green.
(TIF)
Figure S10 Effect of LTCC agonist-induced Zn elevation
on cytokine production. The production of IL-6 and TNF-a
upon antigen stimulation for 3 hours was measured by ELISA in
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BayK8644, an LTCC agonist in (A) and (C). FceRI-mediated
induction of Il6 and Tnfa transcription upon antigen stimulation in
BMMCs with or without treatment with 20 mM (s)-(-)-BayK8644
was determined. The mRNA levels of Il6 and Tnfa were
determined by semi-quantitative RT-PCR analysis in (s)-(-)-
BayK8644-treated cells (B) and (D). N.S., not significant, Student’s
t-test, two-tailed. Bay, (s)-(-)-BayK8644.
(TIF)
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